



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-Entry-fusion complex associated protein OPG095 [M12B9] Ab04475-2.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted mouse IgG2a Fc Silent™ antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Mouse IgG2a, [Fc Silent™](#) , Kappa

Clone Number: M12B9

Alternative Name(s) of Target: L1; L1R; VACV; Protein L1; OPG099; VACWR088; Virion membrane protein M25; EFC-associated protein OPG095

UniProt Accession Number of Target Protein: P07612

Published Application(s): in vivo, neutralization, ELISA, FC

Published Species Reactivity: Vaccinia virus

Immunogen: The original antibody was raised by immunizing a BALB/c mouse with live VACV and refolded L1 protein.

Specificity: This antibody is specific for the L1 protein of the vaccinia virus. Regions 25-34 and 113-131 of L1 are part of the epitope.

Application Notes: A chimeric scFv-Fc version of this antibody was used for an ELISA on recombinant protein L1 of the variola virus strain India-1967, on lysate of MV and EV forms of the vaccinia virus strain LIVP (RU2790134C1), and on overlapping linear biotinylated peptides (Kaeffer et al., 2014; PMID:25031354). The ability of this antibody to protect mice in vivo from VACV challenge was tested on BALB/c mice. The mice were injected with the antibody a day before they were infected with VACV-WR. The antibody is able to prevent death in mice, but it is not able to prevent weight loss (Matho et al., 2015; PMID:26325270). This antibody was used for a FACS based neutralization assay. Here Vero E6 cells were incubated with a mixture of antibody and VACV-GFP and then tested in flow cytometry (Kaeffer et al., 2014; PMID:25031354). This antibody was used for in vivo treatment of mice infected with VACV. It was shown that injection of this antibody after being infected with the virus lead to a 100% survival rate (Zaitseva et al., 2017; PMID:28495463).

Antibody First Published in: Keaver et al. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein J Virol. 2014 Oct;88(19):11339-55.

[PMID:25031354](#)

Note on publication: The original paper generated five murine anti-L1 monoclonal antibodies (MAbs), which clustered into 3 distinct epitope groups. To further understand the protective mechanism of the anti-L1 antibodies.

Product Form

Size: 1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.